Press Releases

Date	Title
May 28, 2019	Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
May 9, 2019	Corcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 3, 2019	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
May 2, 2019	European Medicines Agency Recommends Orphan Drug Designation for Relacorilant to Treat Patients with Cushing’s Syndrome
April 18, 2019	Corcept Therapeutics to Present Data at the 2019 American Association of Clinical Endocrinologists’ 28th Annual Congress
March 20, 2019	Corcept Therapeutics Announces Poster Presentations at the 2019 Annual Meeting of the Endocrine Society Meeting
March 18, 2019	Corcept Therapeutics Appoints Former Amgen Development Executive, Andreas Grauer, M.D., as Chief Medical Officer
February 25, 2019	Corcept Therapeutics Announces Fourth Quarter And Full-Year 2018 Audited Financial Results And Provides Update
February 19, 2019	Corcept Therapeutics To Announce Audited Financial Results, Provide Corporate Update And Host Conference Call
January 31, 2019	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2018 Preliminary Selected Financial Results; Provides 2019 Revenue Guidance